Teveten is a drug owned by Abbvie Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 12, 2014. Details of Teveten's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5656650 | Angiotensin II receptor blocking compositions |
Aug, 2014
(10 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Teveten is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Teveten's family patents as well as insights into ongoing legal events on those patents.
Teveten's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Teveten's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 12, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Teveten Generic API suppliers:
Eprosartan Mesylate is the generic name for the brand Teveten. 1 company has already filed for the generic of Teveten. Check out the entire list of companies who have already received approval for Teveten's generic
How can I launch a generic of Teveten before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Teveten's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Teveten's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Teveten -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 400 mg and 600 mg | 10 May, 2010 | 1 | 16 Nov, 2011 | 12 Aug, 2014 | Eligible |
Alternative Brands for Teveten
Teveten which is used for managing high blood pressure., has several other brand drugs in the same treatment category and using the same active ingredient (Eprosartan Mesylate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbott |
| |||||||||||||||
| Abbvie |
| |||||||||||||||
| Adhera |
| |||||||||||||||
| Allergan |
| |||||||||||||||
| Ani Pharms |
| |||||||||||||||
| Azurity |
| |||||||||||||||
| Boehringer Ingelheim |
| |||||||||||||||
| Cosette |
| |||||||||||||||
| Noden Pharma |
| |||||||||||||||
| Novartis |
| |||||||||||||||
| Upjohn |
| |||||||||||||||
| Waylis Therap |
| |||||||||||||||
Apart from brand drugs containing the same ingredient, some generics have also been filed for Eprosartan Mesylate, Teveten's active ingredient. Check the complete list of approved generic manufacturers for Teveten
About Teveten
Teveten is a drug owned by Abbvie Inc. It is used for managing high blood pressure. Teveten uses Eprosartan Mesylate as an active ingredient. Teveten was launched by Abbvie in 1997.
Approval Date:
Teveten was approved by FDA for market use on 22 December, 1997.
Active Ingredient:
Teveten uses Eprosartan Mesylate as the active ingredient. Check out other Drugs and Companies using Eprosartan Mesylate ingredient
Treatment:
Teveten is used for managing high blood pressure.
Dosage:
Teveten is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 300MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |
| EQ 400MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |
| EQ 600MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |